Mahathir Bayena

Zentek (NASDAQ:ZTEK) said it has secured a pathway to sell its ZenGUARD enhanced air filtration media in the United States through an exclusive eight-year licensing agreement with Applied Silver.

Neurogene (NASDAQ:NGNE) reported updated Phase 1/2 clinical data showing 47 total developmental milestone gains across 10 participants treated with NGN-401 gene therapy for Rett syndrome.

Larimar Therapeutics (NASDAQ:LRMR) announced the submission of the first module of a rolling Biologics License Application to the U.S. Food and Drug Administration seeking accelerated approval of nomlabofusp for the treatment of Friedreich’s ataxia.

Zymeworks has agreed to acquire Theravance Biopharma (NASDAQ:TBPH) for $17 per share in cash.

Senator Cynthia Lummis said JPMorgan Chase CEO Jamie Dimon had misrepresented the Digital Asset Market Clarity Act by claiming it weakens anti-money laundering requirements for cryptocurrency businesses.

BCAL Diagnostics (ASX:BDX), an Australian healthcare company focused on early cancer detection, has secured firm commitments for a further A$4.9 million under its existing A$10 million convertible note facility, with the additional funds to be drawn down as required.

Changpeng Zhao (CZ) said Bitcoin (CRYPTO:BTC) and the broader cryptocurrency market have declined in 2026 because of a combination of geopolitical tensions, capital flowing into artificial intelligence and the sector's historical four-year market cycle.

The stablecoin market has contracted by approximately US$9.45 billion since May 8, reducing the amount of capital available to support cryptocurrency trading as investors continue withdrawing funds from digital asset markets.

Former company director Trent Bowden has pleaded guilty in the Perth Magistrates Court to three charges of dishonestly using his position as director of Trent Bowden Trading Pty Ltd to gain an advantage for himself, in connection with more than $1.5 million of investor funds.

CSL Limited (ASX:CSL) has reported that the European Medicines Agency’s CHMP has issued an opinion recommending the revocation of the EU marketing authorisation for TAVNEOS (avacopan), an in‑licensed therapy sold in EU and EEA markets by CSL Vifor affiliates.